Skip to Content

Drug interactions between Feiba and Hemlibra

Results for the following 2 drugs:
Feiba (anti-inhibitor coagulant complex)
Hemlibra (emicizumab)

Interactions between your drugs


anti-inhibitor coagulant complex emicizumab

Applies to: Feiba (anti-inhibitor coagulant complex) and Hemlibra (emicizumab)

Using anti-inhibitor coagulant complex together with emicizumab may increase the risk of blood clots, which can lead to serious complications such as stroke, pulmonary embolism (blockage of pulmonary artery), heart attack, heart failure, collapse, and kidney failure. In addition, there have been reports of a rare but serious condition called thrombotic microangiopathy (TMA) that results in blood clots forming in small vessels such as those found in the brain and kidneys. Manifestations of TMA include low platelet count, low red blood cell count (anemia), bleeding, bruising, drowsiness, confusion, seizures, and kidney failure. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you experience potential signs and symptoms of blood clots such as chest pain; shortness of breath; coughing up blood; blood in the urine; sudden loss of vision; and pain, redness, or swelling in your arm or leg. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.